Amarantus Bioscience Holdings Inc
Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprieta… Read more
Amarantus Bioscience Holdings Inc (AMBS) - Total Assets
Latest total assets as of March 2023: $10.22 Million USD
Based on the latest financial reports, Amarantus Bioscience Holdings Inc (AMBS) holds total assets worth $10.22 Million USD as of March 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Amarantus Bioscience Holdings Inc - Total Assets Trend (2008–2022)
This chart illustrates how Amarantus Bioscience Holdings Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Amarantus Bioscience Holdings Inc - Asset Composition Analysis
Current Asset Composition (December 2022)
Amarantus Bioscience Holdings Inc's total assets of $10.22 Million consist of 0.3% current assets and 99.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.26K | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2008–2022)
This chart illustrates how Amarantus Bioscience Holdings Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Amarantus Bioscience Holdings Inc's current assets represent 0.3% of total assets in 2022, a decrease from 8.2% in 2008.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2022, down from 8.2% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2008.
- Asset Diversification: The largest asset category is intangible assets at 0.0% of total assets.
Amarantus Bioscience Holdings Inc Competitors by Total Assets
Key competitors of Amarantus Bioscience Holdings Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Amarantus Bioscience Holdings Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Amarantus Bioscience Holdings Inc generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Amarantus Bioscience Holdings Inc is currently not profitable relative to its asset base.
Amarantus Bioscience Holdings Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.00 | 0.00 | 0.03 |
| Quick Ratio | 0.00 | 0.00 | 0.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-34.89 Million | $ -34.72 Million | $ -30.73 Million |
Amarantus Bioscience Holdings Inc - Advanced Valuation Insights
This section examines the relationship between Amarantus Bioscience Holdings Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 53.19 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -30.6% |
| Total Assets | $10.21 Million |
| Market Capitalization | $4.62 USD |
Valuation Analysis
Below Book Valuation: The market values Amarantus Bioscience Holdings Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Amarantus Bioscience Holdings Inc's assets decreased by 30.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Amarantus Bioscience Holdings Inc (2008–2022)
The table below shows the annual total assets of Amarantus Bioscience Holdings Inc from 2008 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | $10.21 Million | -30.59% |
| 2021-12-31 | $14.71 Million | -40.87% |
| 2020-12-31 | $24.87 Million | +0.35% |
| 2019-12-31 | $24.79 Million | +611.67% |
| 2018-12-31 | $3.48 Million | -65.98% |
| 2017-12-31 | $10.24 Million | -8.04% |
| 2016-12-31 | $11.13 Million | -5.41% |
| 2015-12-31 | $11.77 Million | +421.30% |
| 2014-12-31 | $2.26 Million | +21.47% |
| 2013-12-31 | $1.86 Million | +53.64% |
| 2012-12-31 | $1.21 Million | +241.06% |
| 2011-12-31 | $354.76K | +10982.69% |
| 2010-12-31 | $3.20K | -19.02% |
| 2009-12-31 | $3.95K | -18.09% |
| 2008-12-31 | $4.83K | -- |